Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. In the…
Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia - Newscast
Mon, 30 Sep 2024 05:29:00 GMT “We are pleased to share more information on our ongoing Phase 2 MBX 2109 trial in patients with HP ... please visit the Company website at www.mbxbio.com and follow us on LinkedIn. This press release ...
Sun, 22 Sep 2024 19:00:00 GMT MONTPELLIER, France--(BUSINESS WIRE)--Teva presented at ECNP 2024 * new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS ... HERE THE COMPLETE PRESS RELEASE About Medincell ...
Sun, 15 Sep 2024 17:00:00 GMT Sept. 16, 2024 /PRNewswire/ -- Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a Phase 1 trial of TTX-030, a potential first ...
Sat, 14 Sep 2024 05:44:00 GMT Ponsegromab is also being investigated in a Phase 2 study in patients with heart failure (HF) and elevated serum GDF-15 concentrations (NCT05492500). About Cachexia Cachexia is a complex ...
Sat, 14 Sep 2024 00:01:00 GMT In a proffered session to be held on Monday, September 16, 2024, the Company will present translational Phase 1/2 data with KIMMTRAK&circledR ... and the United Kingdom. This press release contains ...
